Medicine
Rhapsido 25 mg tablet
Rhapsido 25 mg tablet is a prescription medicine containing Remibrutinib for oral use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Remibrutinib
- Brand
- Rhapsido
- Strength
- 25 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 60 tablets
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). Dispense and store in the original container in order to protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AA60 Remibrutinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 September 2025
- Identifiers
- RxCUI 2724392, 2724398DailyMed set ID e5e89bff-6ced-4165-acc5-fb13136b3a3dNDC 0078-1483Application NDA218436
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet in 1 bottle | 0078-1483-20 | Novartis Pharmaceuticals | 30 September 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Remibrutinib is a kinase inhibitor indicated for adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of chronic spontaneous urticaria. It is available as tablets for oral use. MedsAcross supplies Remibrutinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RemibrutinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- RHAPSIDO prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Rhapsido: European public assessment report (EPAR) · European Medicines Agency
Need Rhapsido 25 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.